Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04176718 · ClinicalTrials.gov registry record · Phase 2

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

A Phase 2 study of Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Andrew Yee, MD.

Recruiting
Registry status
Phase 2
Development phase
43
Enrollment target
3
Study locations

NCT04176718 is a Phase 2 study of Multiple Myeloma and Refractory Multiple Myeloma that is actively recruiting participants, run by Andrew Yee, MD. The registered enrollment target is 43 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04176718, a Phase 2 study of Multiple Myeloma and Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Andrew Yee, MD.

RECRUITING
Registry status
Phase 2
Development phase
43 participants
Enrollment target
3
Study locations

Study Summary

This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of care drugs involved in this study are: * Dexamethasone * Pomalidomide

Conditions Studied

Multiple Myeloma Refractory Multiple Myeloma Multiple Myeloma in Relapse Relapse

Interventions

  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Pomalidomide
  • DRUG Carfilzomib

Study Locations (3)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston
  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2020-05-18
Est. Completion 2028-05
Phase Phase 2

Sponsor

Andrew Yee, MD

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04176718

The ClinicalTrials.gov registry entry for NCT04176718 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (92% lower). The listed sponsor is Andrew Yee, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.

NCT04176718 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04176718 about?

NCT04176718 is a clinical study titled "Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM". This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. Th...

What is the current status of trial NCT04176718?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2020-05-18. Estimated completion is 2028-05.

What conditions does trial NCT04176718 study?

This clinical trial studies the following conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse.

What interventions are being tested in trial NCT04176718?

The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG).

Who is sponsoring clinical trial NCT04176718?

This trial is sponsored by Andrew Yee, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04176718 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Refractory Multiple Myeloma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.